Skip to content
New patients Save $50 on your hormone panel: $69, normally $119 No insurance · Provider review included · Free priority shipping Check my eligibility
Weight loss

Tirzepatide Results: What the SURMOUNT Trials Reported Over Time

What the SURMOUNT trials reported for branded tirzepatide at weeks 36, 72, 88 and 176, with sources. No photos or testimonials. Not a prediction.

A man in his 40s walking outdoors in a park in the morning, relaxed.

PrescribedRX is a telehealth platform; prescriptions are written by licensed clinicians and filled by licensed partner pharmacies.

Short answer: Tirzepatide “before and after” results in the research are trial averages, not photos. The SURMOUNT trials report average weight change for branded tirzepatide (Zepbound) at set timepoints, not month by month, and none of them studied compounded tirzepatide. In SURMOUNT-1, the average change at 72 weeks (about 17 months) was -15.0% on 5 mg, -19.5% on 10 mg and -20.9% on 15 mg, compared with -3.1% on placebo (Jastreboff et al., NEJM 2022).

This page reports what the published trials measured. It is not a prediction of what any one person will lose, and it is not medical advice. Your provider sets the dose.

For cost and how the online process works, see getting tirzepatide online.

Why does this page have no before-and-after photos?

Most “tirzepatide before and after” results online are photos or personal stories. You can’t check those: you don’t know the dose, the product, the diet or how long it took. This page shows no photos and no testimonials. It reports only the average results that the SURMOUNT trial publications give, at the timepoints those publications give.

What did the trials report, timepoint by timepoint?

Each SURMOUNT trial measured weight at its own main timepoints. The table pulls the headline averages from four publications. Months are approximate (weeks divided by 4.33).

TimepointTrial and who was studiedReported average weight change
Week 36 (about 8 months)SURMOUNT-4 open-label lead-in, adults with obesity or overweight without diabetes, on the highest tolerated dose (10 or 15 mg)-20.9% among the 670 people who completed the lead-in
Week 72 (about 17 months)SURMOUNT-1, 2,539 adults with obesity or overweight without diabetes-15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg), -3.1% (placebo)
Week 72 after a 12-week lifestyle programSURMOUNT-3, 579 adults who had already lost at least 5% with intensive lifestyle changesA further -18.4% (tirzepatide) vs +2.5% (placebo)
Week 88 (about 20 months)SURMOUNT-4, from the start of the lead-in-25.3% (stayed on tirzepatide) vs -9.9% (switched to placebo at week 36)
Week 176 (about 3.4 years)SURMOUNT-1 subgroup with obesity and prediabetes (1,032 people)-12.3% (5 mg), -18.7% (10 mg), -19.7% (15 mg), -1.3% (placebo)

Sources: SURMOUNT-1, SURMOUNT-3, SURMOUNT-4, SURMOUNT-1 three-year analysis. All studied branded tirzepatide, not a compounded product.

Weeks 1 to 20: what happened during dose escalation?

SURMOUNT-1 included a 20-week dose-escalation period at the start of the 72 weeks (Jastreboff et al., 2022). The published abstract does not give an average weight change at week 20. What the authors do report is that the most common side effects were gastrointestinal, mostly mild to moderate, and occurred mainly during dose escalation. For how the Zepbound prescribing information steps the dose, see our tirzepatide dosage chart.

Week 36: what did SURMOUNT-4 report after about 8 months?

In SURMOUNT-4, 783 adults took open-label tirzepatide at their highest tolerated dose (10 or 15 mg) for 36 weeks. The 670 who completed this lead-in had an average weight reduction of 20.9% (Aronne et al., JAMA 2024). This group excludes people who did not finish the lead-in, so it is not directly comparable with the full SURMOUNT-1 population.

Week 72: what did SURMOUNT-1 report after about 17 months?

SURMOUNT-1 is the main obesity trial of tirzepatide. Participants started at an average weight of 104.8 kg and an average BMI of 38.0 (Jastreboff et al., 2022). The authors reported these results at week 72:

GroupAverage weight changeLost 5% or moreLost 20% or more
Tirzepatide 5 mg-15.0%85%Not reported in the abstract
Tirzepatide 10 mg-19.5%89%50%
Tirzepatide 15 mg-20.9%91%57%
Placebo-3.1%35%3%

The same paper reports that adverse events led to stopping treatment in 4.3%, 7.1% and 6.2% of people on 5, 10 and 15 mg, and in 2.6% on placebo.

Week 88 and week 176: what do the longer follow-ups report?

At week 88 in SURMOUNT-4, the average change from the very start was -25.3% for people who stayed on tirzepatide and -9.9% for those switched to placebo at week 36 (Aronne et al., 2024).

The three-year SURMOUNT-1 analysis followed participants who had both obesity and prediabetes for 176 weeks. It reported average changes of -12.3% (5 mg), -18.7% (10 mg) and -19.7% (15 mg), compared with -1.3% on placebo (Jastreboff et al., NEJM 2025). The authors also reported that 1.3% of the tirzepatide groups and 13.3% of the placebo group were diagnosed with type 2 diabetes during that period.

What did the trials report when people stopped tirzepatide?

SURMOUNT-4 was designed to test this. After the 36-week lead-in, people were randomly assigned to keep taking tirzepatide or switch to placebo for 52 more weeks. From week 36 to week 88, the average weight change was -5.5% for those who continued and +14.0% for those switched to placebo. At week 88, 89.5% of the continued group had kept at least 80% of the weight they lost in the lead-in, compared with 16.6% of the placebo group (Aronne et al., 2024). The authors concluded that withdrawing tirzepatide led to substantial regain of lost weight.

Does tirzepatide work?

The evidence published so far comes from trials of branded tirzepatide. In each placebo-controlled comparison in the table above, the authors reported a larger average weight reduction in the tirzepatide groups than in the placebo group, and SURMOUNT-1 reported P below 0.001 for every dose compared with placebo (Jastreboff et al., 2022). These are group averages. The same trial reports that 85% to 91% of people on tirzepatide reached at least a 5% reduction, depending on dose, so not everyone did. Whether tirzepatide is appropriate for you is a question for a licensed provider.

If you are weighing it against semaglutide, our tirzepatide vs semaglutide trial comparison sets the two sets of trials side by side.

When should you call a doctor?

The Zepbound prescribing information describes the signs below and tells patients to contact their healthcare provider, or get medical help, if they notice them (Zepbound prescribing information):

  • Severe stomach pain that does not go away, with or without vomiting (possible pancreatitis)
  • Pain in the upper right belly, fever, yellow skin or eyes, or clay-colored stools (possible gallbladder problems)
  • Signs of dehydration, such as very little urine, dizziness or extreme thirst, which can strain the kidneys
  • Shakiness, sweating, confusion or a fast heartbeat if you also take insulin or a sulfonylurea (low blood sugar)
  • Swelling of the face, lips or throat, trouble breathing or a severe rash (allergic reaction)
  • A lump or swelling in the neck, trouble swallowing or a hoarse voice that will not go away

The Zepbound prescribing information includes a boxed warning: it reports that tirzepatide caused thyroid C-cell tumors in rats, and Zepbound is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) (Zepbound prescribing information). Our tirzepatide safety information page covers more safety information.

What about tirzepatide reviews?

PrescribedRX doesn’t publish patient reviews or testimonials about tirzepatide. Individual stories can’t tell you what is typical. The averages and ranges in the trials above, with their placebo groups, are the most complete published picture. For the side effects listed in the Zepbound prescribing information, see our page on tirzepatide side effects.

Do these results apply to compounded tirzepatide?

Not directly: no trial in this table studied a compounded product. The SURMOUNT trials studied branded tirzepatide made by Eli Lilly and sold as Zepbound (Zepbound prescribing information). Compounded tirzepatide is prepared by licensed pharmacies and is a different product, so these trial results do not automatically apply to it.

How does tirzepatide work with PrescribedRX?

You start with a short online eligibility check. A licensed provider reviews your answers, typically within 48 hours, and a prescription is issued only if a licensed provider determines treatment is appropriate. If one is issued, a licensed partner pharmacy fills compounded tirzepatide. Compounded medications are prepared by licensed pharmacies and are not FDA-approved. Plans are self-pay with no insurance, shipping is free priority, and availability varies by state. Your provider sets the dose.

  • Compounded tirzepatide: 3 month plan $597 · $199/mo · Billed every 3 months. Cancel anytime.

See the compounded tirzepatide plan for what each shipment includes, our tirzepatide cost breakdown for how pricing compares, or browse all weight loss treatments.

Related reading: semaglutide results by timepoint · Retatrutide vs Tirzepatide: What the Trials Report

Sources

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed. Accessed Oct 2026.
  2. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PubMed. Accessed Oct 2026.
  3. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918. PubMed. Accessed Oct 2026.
  4. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958-971. PubMed. Accessed Oct 2026.
  5. DailyMed. Zepbound (tirzepatide) injection, prescribing information. National Library of Medicine, NIH. dailymed.nlm.nih.gov. Accessed Oct 2026.

This article is for general information. It is not medical advice and it is not a recommendation for any particular treatment. Whether a treatment is appropriate for you is a decision for a licensed clinician who has reviewed your health history and current medications.

Share X Facebook Email

This article is for information only and is not medical advice. Treatment is prescribed solely at the discretion of a licensed provider following a clinical evaluation.

A woman in her 40s eating a small balanced meal at a table, salad and grilled fish, natural light. Eating on GLP-1 Medications: What Prescribing Information and Guidance Say A man with a gray beard reading a printed research article at a dining table Retatrutide vs Tirzepatide: What the Trials Report A woman in her 40s on a video call with a clinician on a laptop at home. Mochi Health Review 2026: Cost, Process and Refund Terms

Two minutes to find out if it fits

Answer a few questions and a licensed provider takes it from there. Every price is on the page, and nothing is prescribed unless it is appropriate for you.

Check my eligibility